KUALA LUMPUR, April 15 (Bernama) -- Koelis, SAS (Koelis or the Company) has announced the completion of a €10 million follow-on growth equity financing led by InnovaHealth Partners, LP (InnovaHealth) and certain affiliates. (€1 = RM4.574)
Koelis is a pioneer and leader in the market for image-guided prostate cancer interventions including biopsy diagnosis and minimally invasive treatments, while InnovaHealth Partners, is a leading private equity firm focused on providing growth equity to the medical device industry.
According to a statement, the financing will support the Company’s continued commercial expansion as well as its commitment to clinical and technology initiatives that are at the leading edge of a paradigm shift in the diagnosis and treatment of prostate cancer.
InnovaHealth President & CEO, Mortimer ‘Tim’ Berkowitz III said: “In advancing the way prostate cancer is diagnosed and treated, we see the enormous potential of Koelis technology to address significant unmet clinical needs on a global basis.”
Meanwhile, Koelis Co-founder and Chief Executive Officer, Antoine Leroy said: “We are very pleased to complete this financing with the InnovaHealth Partners team that has been not just a supportive investor, but also a true partner who shares the Koelis vision to be a leader in the transformation of the diagnosis and treatment of prostate cancer.”
The Koelis Trinity is a system that offers stand-alone ultrasound imaging and MRI fusion image guidance for prostate biopsy and minimally invasive prostate cancer treatments.
Featuring proprietary 3D ultrasound imaging and prostate motion tracking software (OBT Fusion®), the Koelis Trinity System facilitates more accurate biopsy diagnosis as well as enabling ‘focal’ treatment alternatives to traditional ‘total organ’ treatments such as surgical prostatectomy and radiation.
-- BERNAMA
No comments:
Post a Comment